Endogenous peptide
Kisspeptin
Kisspeptin is an endogenous signalling peptide with physiological relevance; therapeutic administration remains molecule- and indication-specific.
Evidence confidence
Human
5/5
Strong human clinical evidence
5 citations
Animal
Not yet assessed
Trust Engine review pending.
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
4/5
Well-characterised safety
4 citations
Claimed uses
- Weak
- Weak
- Limited to moderate
Mechanisms
Safety notes
Exogenous administration can produce systemic effects and requires indication-specific dosing and monitoring.
Regulation
- Research.
- Research-stage for libido-related use; not a generally licensed libido treatment.
- Regulatory status depends on formulation, indication and jurisdiction.
References
- Intravenous kisspeptin 112-121 bolus does not acutely impact circulating vasopressin in humans · 2026
- Kisspeptin and neurokinin B: roles in reproductive health · 2025
- Sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans · 2025
- Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder · 2023
- The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction · 2022
- Stress, kisspeptin, and functional hypothalamic amenorrhea · 2022
- Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder · 2022
- Kisspeptin modulates sexual and emotional brain processing in humans · 2017
Last reviewed
12 July 2026